ESR1 and breast carcinoma: The loss of ERα gene expression is a key factor in breast cancer progression, and it is associated with a more aggressive tumor phenotype and loss of sensitivity to endocrine therapy drugs such as tamoxifen (Singh et al., 2003), the most widely used anti-estrogen in clinical practice (Kurokawa and Arteaga, 2001; Zheng et al., 2015).